POET Technologies Lands $500M Lumilens Order as Lawsuits and Production Hurdles Loom

Optical chipmaker POET secures a strategic partnership worth up to $500M but faces twin class actions over tax disclosures and confidentiality issues.

POET Technologies finds itself straddling two wildly different narratives. On one side, the optical chipmaker has just inked a strategic partnership with Lumilens that could be worth more than half a billion dollars over five years. On the other, it faces a pair of federal securities class actions over its handling of tax disclosures and customer confidentiality — allegations that sent the stock into a 47% tailspin just weeks ago.

Investors got a taste of the upside first. The Lumilens deal, announced after the close, triggered a 24% pre-market surge to $17.84. The agreement includes an initial purchase order of $50 million for optical components built on POET’s EOI platform, which fuses electronic and photonic circuitry at the wafer level to relieve data bottlenecks in AI clusters and cloud data centers. If the relationship scales as projected, cumulative revenue could exceed $500 million by 2031.

To cement the tie-up, Lumilens receives options on roughly 23 million POET shares at an exercise price of $8.25. The two companies will jointly develop pluggable transceivers and co-packaged optics for high-speed networks, targeting engineering samples by the end of 2026 and mass production in 2027.

Legal storm casts a shadow

The celebration is tempered by a legal assault that targets the company’s credibility. Faruqi & Faruqi has filed a nationwide securities class action, giving investors until June 29, 2026, to seek lead-plaintiff status. Bernstein Liebhard has filed a separate complaint covering buyers of POET shares between April 1 and the morning of April 27, 2026.

At the heart of both suits are two allegations. First, POET is accused of misrepresenting its exposure to the passive foreign investment company (PFIC) tax classification — a status that can create unpleasant tax consequences for U.S. holders if not properly reported. Second, the company allegedly breached confidentiality obligations by disclosing order and delivery details related to Marvell, which reportedly objected to the disclosure. The fallout was brutal: the stock cratered from $15.10 to $7.95 — a single-day loss of $7.15 per share.

The legal risk is especially acute for a firm with minimal revenue. For the first quarter, analysts expect POET to report a loss of $0.04 per share on sales of just $250,000. The most recent quarter didn’t offer much more: non-recurring engineering and product revenue totaled $341,202, up from $29,032 a year earlier, but the net loss hit $42.7 million. For the full 2025 year, revenue was barely $1 million against a net loss of nearly $63 million.

Deep pockets and a new operations chief

Despite the headwinds, POET has built a financial cushion. After a $225 million capital raise in the fourth quarter followed by a $150 million injection in January, cash and short-term investments stand at roughly $313 million. The company carries little debt and maintains a current ratio above 2.0, signaling ample short-term liquidity.

That war chest will fund a production ramp that now has a new leader. Dr. Sandeep Kumar, a former 18-year veteran of Silicon Labs, became chief operating officer on May 11, 2026, reporting directly to the CEO. He received 410,397 restricted share units with a mandate to scale up global manufacturing — particularly the Malaysian facility where POET plans to produce optical engines and light sources in volume.

The production timeline remains ambitious. The company targets manufacturing readiness for light sources in the second quarter of this year, with 800G high-speed engines following in the third. Management expects to ship more than 30,000 optical engines in total during 2026.

A leveraged ETF adds fuel

Traders have a new tool to bet on the volatility. Defiance ETFs launched the Defiance Daily Target 2X Long POET ETF, offering short-term leveraged exposure to the stock. While the fund does nothing for the fundamentals, it could amplify daily swings in volume and price — for good or ill.

All of these threads converge on May 20, when POET reports first-quarter results. The market will focus less on the $250,000 revenue line than on three key indicators: cash burn, any new disclosures about the lawsuits, and tangible progress in Malaysia. With a $2 billion-plus valuation propped by little more than promise, the next few weeks will test whether the Lumilens deal can outshine the legal clouds gathering overhead.